Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial

Por Spielmann, M, Tubiana-Hulin, M, Namer, M, Mansouri, H, Bougnoux, P h, Tubiana-Mathieu, N, Lotz, V, Eymard, J C
Publicado em 2002

Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

Por Bonneterre, J, Dieras, V, Tubiana-Hulin, M, Bougnoux, P, Bonneterre, M-E, Delozier, T, Mayer, F, Culine, S, Dohoulou, N, Bendahmane, B
Publicado em 2004

Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion

Por Vinholes, J, Coleman, R, Lacombe, D, Rose, C, Tubiana-Hulin, M, Bastit, P, Wildiers, J, Michel, J, Leonard, R, Nortier, J, Mignolet, F, Ford, J
Publicado em 1999

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.

Por Ralston, S. H., Thiébaud, D., Herrmann, Z., Steinhauer, E. U., Thürlimann, B., Walls, J., Lichinitser, M. R., Rizzoll, R., Hagberg, H., Huss, H. J., Tubiana-Hulin, M., Body, J. J.
Publicado em 1997

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis

Por Dufresne, A, Bertucci, F, Penel, N, Le Cesne, A, Bui, B, Tubiana-Hulin, M, Ray-Coquard, I, Cupissol, D, Chevreau, C, Perol, D, Goncalves, A, Jimenez, M, Bringuier, P P, Blay, J Y
Publicado em 2010

Identification of molecular apocrine breast tumours by microarray analysis

Por Farmer, P, Bonnefoi, H, Becette, V, Tubiana-Hulin, M, Fumoleau, P, Larsimont, D, MacGrogan, G, Bergh, J, Cameron, D, Goldstein, D, Duss, S, Nicoulaz, A-L, Fiche, M, Brisken, C, Delorenzi, M, Iggo, R
Publicado no Breast Cancer Res (2005)